What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
The World Health Assembly has adopted a resolution recognizing skin diseases, including psoriasis, as a global public health priority. This opens the door to improved care, research, and awareness.
Learn about the relationship between psoriasis, obesity, and systemic inflammation, and how GLP-1 agonists, originally developed for type 2 diabetes and obesity, may offer a future treatment option for psoriasis and related inflammatory conditions.
Discover the new free psoriasis course on WHOAcademy, created by IPC and IFPA for the WHO. Enhance your knowledge of psoriasis epidemiology, diagnosis, and management.
The 2025 AAD Annual Meeting featured important updates on psoriasis therapies, comorbidities, and late-breaking research. Read the highlights from top dermatologists and international experts.
IPC Councilor Ulrich Mrowietz, founder of the Psoriasis Center at University Medical Center Schleswig-Holstein, discusses psoriasis as a systemic disease with comorbidities like cardiovascular diseases and neuroinflammation. He emphasizes the importance of a multidisciplinary approach and ongoing research for better patient outcomes.
Learn about the new global diagnostic criteria for Generalized Pustular Psoriasis as set by the International Psoriasis Council. Discover the essential features, the importance of accurate diagnosis, and the expected global impact on patient care.
Learn how our concise instructional videos assist health care professionals in preparing psoriasis patients for telemedicine dermatology appointments. Available in English and Spanish, these guides cover optimal photo-taking techniques and essential preparation tips, facilitating streamlined virtual consultations.
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases.
New resource page that includes the latest articles, downloads, and related press releases on GPP to assist with diagnosing and treating this rare disease.
Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years.
Claro, a digital platform built to improve mental health for those with psoriasis who are living in Spain, the United Kingdom, and Italy.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
